LONDON: Nestle, the world’s biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros (US$111mil) to develop and market an experimental milk allergy test for infants.
The Swiss group would pay DBV Technologies 10 million euros upfront for rights to its skin patch test for cow’s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said yesterday.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
